• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    2/9/22 3:43:36 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DARE alert in real time by email
    SC 13G/A 1 tv0711-darebioscienceinc_b.htm SCHEDULE 13G/A darebioscienceinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Dare Bioscience Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  23666P101

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  23666P101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    8,780

    7.  SOLE DISPOSITIVE POWER

    3,030,136

    8.  SHARED DISPOSITIVE POWER

    25,917

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,056,053

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    3.99%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    13G

    CUSIP No.:  23666P101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund - 23-2671505

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Delaware

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    2,082,157

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    0

    8.  SHARED DISPOSITIVE POWER

    0

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,082,157

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.72%

    12.  TYPE OF REPORTING PERSON

    IV

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Dare Bioscience Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3655 Nobel Drive, Suite 260
    San Diego, CA 92122

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund - 23-2671505

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    The Vanguard Group
    Pennsylvania

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund
    Delaware

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    23666P101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  The Vanguard Group: An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). Vanguard Index Funds - Vanguard Total Stock Market Index Fund: Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    The Vanguard Group

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Vanguard Index Funds - Vanguard Total Stock Market Index Fund

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Chief Financial Officer and Acting Treasurer of the Vanguard Funds

    Get the next $DARE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DARE

    DatePrice TargetRatingAnalyst
    6/30/2021$9.00 → $11.00Buy
    Roth Capital
    More analyst ratings

    $DARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Rastetter William H

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    7/10/25 4:05:59 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Steele Robin Joan

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    7/10/25 4:05:47 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Matz Gregory W

    4 - Dare Bioscience, Inc. (0001401914) (Issuer)

    7/10/25 4:05:37 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    SEC Filings

    View All

    SEC Form 10-Q filed by Dare Bioscience Inc.

    10-Q - Dare Bioscience, Inc. (0001401914) (Filer)

    8/14/25 4:04:02 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dare Bioscience Inc. filed SEC Form 8-K: Other Events

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    7/25/25 8:00:27 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dare Bioscience Inc. filed SEC Form 8-K: Other Events

    8-K - Dare Bioscience, Inc. (0001401914) (Filer)

    7/18/25 5:48:56 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Dare Bioscience with a new price target

    Roth Capital reiterated coverage of Dare Bioscience with a rating of Buy and set a new price target of $11.00 from $9.00 previously

    6/30/21 9:55:24 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting ContraceptionFour Commercially Available Solutions for Women on the Horizon In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and Proprietary Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Late 2026Creates Entry into the Estimated $4.5 Billi

    8/14/25 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

    SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2684883. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.d

    8/7/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

    A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce

    7/29/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Leadership Updates

    Live Leadership Updates

    View All

    Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

    A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness' extensive reach and community of over 250,000 women; campaign designed to drive awareness and support women with arousal concerns SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, and Rosy Wellness, a pioneering digital platform focused on providing lifespan support for women, today announce

    7/29/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Announces Executive Team and Board of Directors Changes

    SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh

    1/26/24 4:30:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors

    SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. "We are thrilled to add Dr. Ononye-Onyia to the Daré Board," said Sabrina Martucci Johnson, Daré's President and CEO. "Sophia has demonstrated the value of her leadership to global biopharmaceutical companies throughout her career. Her experience supporting commercialization of women's health products positions her to provide strategic guidance as our product candidates advance toward commercialization, and as we explore the variety of go-to-market partnering strategies

    4/19/21 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:36 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Dare Bioscience Inc. (Amendment)

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/9/22 3:43:35 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Dare Bioscience, Inc. (0001401914) (Subject)

    2/12/21 5:13:06 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DARE
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting ContraceptionFour Commercially Available Solutions for Women on the Horizon In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and Proprietary Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Late 2026Creates Entry into the Estimated $4.5 Billi

    8/14/25 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

    SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2684883. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.d

    8/7/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

    Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profitabilityDaré expects to start recording revenue in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the further expanded business strategy to commercialize multiple solutions in 2025 and 2026 2025 and 2026 Milestones Sildenafil Cream, 3.6% an investigational topical formulation of sildenafil being developed to treat female sexual arousal disorder, targeting availability via prescription as a Section 503B compounded drug t

    5/13/25 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care